Orientations provisoires
9 août 2021
Le présent document vise à décrire un ensemble minimal d'activités de surveillance recommandées au niveau national pour détecter et surveiller la prévalence relative des variantes du SRAS-CoV-2 et à présenter un ensemble d'activités pour la caractér...isation et l'évaluation du risque que présentent ces variantes. k posés par ces variants. Un ensemble d'indicateurs est également fourni pour normaliser la surveillance et la déclaration publique de la circulation des variants.
Ce document est principalement destiné aux autorités de santé publique nationales et infranationales et aux partenaires qui soutiennent la mise en œuvre de la surveillance des variantes du SRAS-CoV-2.
more
Временные рекомендации
9 августа 2021 г.
Цель данного документа - описать минимальный набор мероприятий по эпиднадзору, рекомендуемых на национальном уровне для вы...вления и мониторинга относительной распространенности вариантов SARS-CoV-2, и наметить набор мероприятий для характеристики и оценки риска, создаваемого этими вариантами. Также приводится набор показателей для стандартизации мониторинга и публичной отчетности о циркуляции вариантов.
Документ предназначен в первую очередь для национальных и субнациональных органов здравоохранения и партнеров, поддерживающих внедрение эпиднадзора за вариантами SARS-CoV-2.
more
Orientaciones provisionales
9 de agosto de 2021
El presente documento tiene por objeto describir un conjunto mínimo de actividades de vigilancia recomendadas a nivel nacional para detectar y supervisar la prevalencia relativa de las variantes del SRAS-CoV-2 y esbozar un conjunto de actividades pa...ra la caracterización y evaluación del riesgo que plantean estas variantes. También se ofrece un conjunto de indicadores para normalizar la vigilancia y la notificación pública de la circulación de variantes.
El documento está dirigido principalmente a las autoridades de salud pública nacionales y subnacionales y a los socios que apoyan la aplicación de la vigilancia de las variantes del SRAS-CoV-2
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...vamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas.
more
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian...ts; and (iv) how populations understand these dynamics, perceive risk and follow control measures, including public health and social measures (PHSM).
more
Why bold action against inequalities is needed to en AIDS, stop COVID-19 and prepare for future pandemics
The strategy recommends that AU Member States should enhance, where feasible, existing COVID-19 surveillance to include:
Community-based surveillance to detect symptomatic cases early for treatment and to avert viral transmission;
Sentinel surveillance in high-risk populations to detect ...and track both presymptomatic and asymptomatic cases; and
Wastewater surveillance to monitor early environmental signs of virus transmission and identify communities where targeted interventions can be implemented to decrease transmission.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
orientations provisoires, première publication le 25 janvier 2021, mise à jour le 15 juin 2021, mise à jour le 19 novembre 2021
Climate change and health vulnerability and adaptation assessment
In 2013 the World Health Organization (WHO) published the report Protecting health from climate change:
vulnerability and adaptation assessment. The aim was to provide basic and flexible guidance on conducting national or subnati...onal assessments of current and future vulnerability (the susceptibility of a population or region to harm) to the health risks of climate change, and of policies and programmes that could increase resilience, taking into account the multiple determinants of climate-sensitive health outcomes.
That guidance has been a very useful tool, applied to more than 50 countries and settings, and has helped countries to prepare their health contributions to United Nations Framework Convention on Climate Change national adaptation plans.
Since the launch of the guidance, WHO, technical partners such as Health Canada, and countries have learned much in terms of its applicability in different countries, at national and local levels.
At the same time, knowledge on climate change and health has increased.
WHO, the Pan American Health Organization and Health Canada have produced this updated version, which aims to better support countries in their assessments by proposing a simpler tool that incorporates all lessons learned.
more
Updated Treatment Guidelines